Medication info
Coprazole Tablet 20 mg (Esomeprazole Magnesium Trihydrate)

Coprazole Tablet 20 mg (Esomeprazole Magnesium Trihydrate)

Prescription medicationTablet
Ingredient · strength
Esomeprazole Magnesium Trihydrate›22.25mg / 1 tablet
Manufacturer / importer
Kohwang Pharmaceutical Co., Ltd.
Appearance
Pale pink round film-coated tablet
Packaging
28 tablets - 14 tablets/Alu-Alu[X2], 28 tablets - 7 tablets/Alu-Alu[X4]
Approval status
Active

MFDS item code 201403819 · Approved 2014.08.19 · Insurance code 670303830

Summary

Main use
Treatment of acid-related disorders (reflux, ulcers, etc.) and Helicobacter pylori eradication; treatment of gastrointestinal disorders caused by nonsteroidal anti-inflammatory drugs
Who uses it
Adults · Children
Adult dosage
1. Adults 1) Gastroesophageal reflux disease (GERD). - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. Patients whose esophagitis has not healed or whose symptoms persist should take the medicine for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is needed. · Once symptoms have resolved, subsequent recurrent symptoms are controlled by administering 20 mg once daily. · In adults, 20 mg may be taken once daily as needed. As-needed administration to control recurrent symptoms is not recommended for patients at high risk of gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug use. 2) Combination therapy with antibiotics for eradication of Helicobacter pylori Administer this medicine 20 mg in combination with amoxicillin 1 g and clarithromycin 500 mg, twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, burning sensation) associated with use of nonsteroidal anti-inflammatory drugs (nonselective or selective COX-2 inhibitors) - 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is needed. Clinical studies lasting longer than 4 weeks have not been conducted. 4) Patients requiring continued use of nonsteroidal anti-inflammatory drugs - Treatment of gastric ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. The treatment period is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The dose should then be adjusted for each patient, and treatment should continue while clinical symptoms are present. Clinical data indicate that most patients can be controlled with doses of 80 ∼ 160 mg per day. Doses above 80 mg per day should be divided into 2 daily doses. 6) Maintenance therapy following intravenous induction for prevention of rebleeding from gastric or duodenal ulcers Administer 40 mg once daily for 4 weeks following intravenous induction for prevention of rebleeding from gastric or duodenal ulcers. 4. Renal impairment: No dose adjustment is necessary. Use with caution because experience in patients with severe renal failure is limited. 5. Hepatic impairment: No dose adjustment is necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the dose of this medicine should not exceed 20 mg. 6. Elderly patients: No dose adjustment is necessary.
Children's dosage
2. Adolescents aged 12 years and older 1) Gastroesophageal reflux disease (GERD) - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. If esophagitis has not healed or symptoms persist, continue treatment for an additional 4 weeks. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms have resolved, subsequent recurrent symptoms may be controlled with 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. As-needed administration to control recurrent symptoms is not recommended for patients at high risk of gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug use. 3. Children under 12 years of age: There is no experience with administration of this drug to children under 12 years of age.

Ingredients

Manufacturer
Kohwang Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of acid-related disorders (reflux, ulcers, etc.) and Helicobacter pylori eradication; treatment of gastrointestinal disorders caused by nonsteroidal anti-inflammatory drugs

  • Gastroesophageal reflux disease
  • erosive reflux esophagitis
  • esophagitis
  • Helicobacter pylori-positive duodenal ulcers
  • peptic ulcers
  • upper gastrointestinal symptoms
  • pain
  • discomfort
  • burning sensation
  • gastric ulcers
  • duodenal ulcers
  • Zollinger-Ellison syndrome
View approved original text

This medication is used for the long-term maintenance therapy of gastroesophageal reflux disease, particularly erosive reflux esophagitis. It also helps alleviate symptoms in patients with gastroesophageal reflux disease without esophagitis. It is effective in the treatment and prevention of recurrence of duodenal ulcers and peptic ulcers due to Helicobacter pylori infection. It provides short-term treatment of gastrointestinal symptoms associated with non-steroidal anti-inflammatory drugs and is also used for the treatment and prevention of gastric ulcers in patients requiring long-term therapy. It is utilized in the treatment of Zollinger-Ellison syndrome and maintenance therapy to prevent rebleeding from gastric and duodenal ulcers. Overall, it is used effectively to treat and prevent various symptoms and diseases related to gastrointestinal disorders.

Dosage and Administration

Adult dosage

1. Adults 1) Gastroesophageal reflux disease (GERD). - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. Patients whose esophagitis has not healed or whose symptoms persist should take the medicine for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is needed. · Once symptoms have resolved, subsequent recurrent symptoms are controlled by administering 20 mg once daily. · In adults, 20 mg may be taken once daily as needed. As-needed administration to control recurrent symptoms is not recommended for patients at high risk of gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug use. 2) Combination therapy with antibiotics for eradication of Helicobacter pylori Administer this medicine 20 mg in combination with amoxicillin 1 g and clarithromycin 500 mg, twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, burning sensation) associated with use of nonsteroidal anti-inflammatory drugs (nonselective or selective COX-2 inhibitors) - 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is needed. Clinical studies lasting longer than 4 weeks have not been conducted. 4) Patients requiring continued use of nonsteroidal anti-inflammatory drugs - Treatment of gastric ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. The treatment period is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The dose should then be adjusted for each patient, and treatment should continue while clinical symptoms are present. Clinical data indicate that most patients can be controlled with doses of 80 ∼ 160 mg per day. Doses above 80 mg per day should be divided into 2 daily doses. 6) Maintenance therapy following intravenous induction for prevention of rebleeding from gastric or duodenal ulcers Administer 40 mg once daily for 4 weeks following intravenous induction for prevention of rebleeding from gastric or duodenal ulcers. 4. Renal impairment: No dose adjustment is necessary. Use with caution because experience in patients with severe renal failure is limited. 5. Hepatic impairment: No dose adjustment is necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the dose of this medicine should not exceed 20 mg. 6. Elderly patients: No dose adjustment is necessary.

Children's dosage

2. Adolescents aged 12 years and older 1) Gastroesophageal reflux disease (GERD) - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. If esophagitis has not healed or symptoms persist, continue treatment for an additional 4 weeks. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms have resolved, subsequent recurrent symptoms may be controlled with 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. As-needed administration to control recurrent symptoms is not recommended for patients at high risk of gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug use. 3. Children under 12 years of age: There is no experience with administration of this drug to children under 12 years of age.

Precautions

This medication should not be used by patients who have had allergic reactions to specific ingredients or benzimidazole derivatives. It should not be administered in cases of allergy to antibiotics such as amoxicillin or clarithromycin used together with this medication. Additionally, patients taking certain heart-related medications or with a history of myocardial infarction, as well as breastfeeding women, should not take this medication. This medication contains a dye called Yellow No. 5, and those who are allergic or hypersensitive to this component should use it cautiously. During use, it may rarely cause side effects such as decreased blood cell count, allergic reactions, hypomagnesemia, headaches, abdominal pain, skin rashes, etc., so if unusual symptoms occur, immediate consultation with a physician is required. Long-term use of this medication requires regular testing, especially if taken for more than a year, due to potential issues such as fracture risks or hypomagnesemia. This medication can reduce stomach acid, potentially increasing bacterial growth in the stomach, which may slightly increase the risk of infections such as diarrhea; thus, if diarrhea persists, it should be reported to a healthcare professional. When taken with other drugs, it may affect the absorption or effectiveness of those medications, especially when combined with antiviral agents, anticoagulants, antibiotics, etc., so it should be used according to a professional's guidance. During pregnancy, safety data is limited, so pregnant women must consult a physician before use, and it is advisable for breastfeeding women to avoid taking this medication. In cases of overdose, there is no specific antidote, so one should immediately visit a medical institution for appropriate treatment, and it should be kept out of the reach of children.

Side effects

Leukopenia, thrombocytopenia, agranulocytosis, pancytopenia, fever, angioedema, anaphylactic reaction, shock, peripheral edema, hyponatremia, hypomagnesemia, insomnia, anxiety, confusion, depression, aggression, hallucination, headache, dizziness, paresthesia, drowsiness, taste disorder, blurred vision, bronchospasm, pancreatitis, abdominal pain, constipation, diarrhea, abdominal bloating, nausea, vomiting, dry mouth, stomatitis, gastrointestinal candidiasis, microscopic colitis, increased liver enzymes, hepatitis, liver failure, encephalopathy, dermatitis, itching, rash, urticaria, hair loss, photosensitivity, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, drug reaction with eosinophilia and systemic symptoms, fracture, arthralgia, myalgia, muscle weakness, interstitial nephritis, gynecomastia, asthenia, increased sweating, Clostridium difficile-associated diarrhea, abdominal bloating, allergic reaction, back pain, chest pain, substernal pain, facial edema, facial flushing, fatigue, influenza-like illness, generalized edema, leg edema, malaise, pain, stiffness, anemia, hypopigmented anemia, cervical lymphadenopathy, epistaxis, leukocytosis, leukopenia, thrombocytopenia, hyperbilirubinemia, liver dysfunction, increased ALT, increased AST, diabetes, hyperuricemia, increased ALP, polydipsia, vitamin B12 deficiency, weight gain, weight loss, exacerbation of arthritis, arthropathy, cramps, fibromyalgia syndrome, hernia, rheumatoid polymyalgia, loss of appetite, apathy, increased appetite, confusion, worsening depression, hypertonia, sensory loss, erectile dysfunction, insomnia, migraine, exacerbation of migraine, sleep disorders, tremor, visual field defect, dysmenorrhea, menstrual disorders, vaginitis, exacerbation of asthma, cough, shortness of breath, laryngeal edema, pharyngitis, rhinitis, sinusitis, acne, anal itching, erythematous rash, papular rash, otitis media, altered smell, taste loss, taste distortion, abnormal urination, albuminuria, cystitis, dysuria, fungal infection, hematuria, urinary frequency, candidiasis, genital candidiasis, polyuria, conjunctivitis, visual disturbances, duodenitis, esophagitis, esophageal stricture, esophageal ulcer, esophageal varices, gastric ulcer, gastritis, benign polyp or nodule, Barrett's esophagus, mucosal discoloration, hernia, systemic lupus erythematosus, cutaneous lupus erythematosus, gastric fundic polyp, hypocalcemia, hypokalemia, rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture. Additionally, it should be stored at room temperature between 1 and 30 degrees Celsius, not in extremely hot or cold areas.

Appearance and packaging

Appearance

Pale pink round film-coated tablet

Package unit

28 tablets - 14 tablets/Alu-Alu[X2], 28 tablets - 7 tablets/Alu-Alu[X4]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.